Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

199
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
199
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

790
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
790
Physical Properties of Amines01:26

Physical Properties of Amines

4.1K
Amines with low molecular weight are usually gaseous at room temperature, while those with high molecular weight are liquid or solids in nature. Usually, low molecular weight amines have a rotten fish-like smell. Diamines typically have a pungent smell. For instance, cadaverine and putrescine, depicted in Figure 1, are two molecules responsible for decaying tissue.
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

School is more than a place to learn: An intersectoral assessment of adolescent well-being prior to and after the COVID-19 pandemic in the WHO European Region.

Public health in practice (Oxford, England)·2025
Same author

Ultrafast phonon-mediated dephasing of color centers in hexagonal boron nitride probed by electron beams.

Nature communications·2025
Same author

3D printer emissions elicit filament-specific and dose-dependent metabolic and genotoxic effects in human airway epithelial cells.

Frontiers in public health·2024
Same author

What's love got to do with it? Exploring social love and public health.

Perspectives in public health·2024
Same author

Relationship between in feed drugs, antibiotics and organic enrichment in marine sediments at Canadian Atlantic salmon aquaculture sites.

Marine pollution bulletin·2023
Same author

Metabolization of emamectin benzoate into desmethyl emamectin benzoate in spiked marine sediments.

Chemosphere·2022
Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026
Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026
Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026
Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026
Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026
Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026
See all related articles

Related Experiment Videos

Acetaminophen hepatotoxicity.

M Black

    Annual Review of Medicine
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Acetaminophen hepatotoxicity can occur even at therapeutic doses, especially in alcohol consumers. Increased awareness and improved drug labeling are recommended to prevent liver damage from this common pain reliever.

    Related Experiment Videos

    Area of Science:

    • Pharmacology
    • Toxicology
    • Hepatology

    Background:

    • Acetaminophen (APAP) is a widely used analgesic and antipyretic.
    • Hepatotoxicity is a known risk associated with acetaminophen overdose.
    • Increasing recognition of liver injury from therapeutic acetaminophen use.

    Purpose of the Study:

    • To review the history and current use of acetaminophen.
    • To discuss the molecular mechanisms of acetaminophen-induced liver injury.
    • To outline clinical manifestations, treatment, and risk factors.

    Main Methods:

    • Literature review of acetaminophen hepatotoxicity.
    • Discussion of molecular pathways.
    • Analysis of clinical case reports and epidemiological data.

    Main Results:

    • Massive overdose remains a common cause of acetaminophen hepatotoxicity.
    • Hepatotoxicity is increasingly observed with therapeutic acetaminophen ingestion.
    • Alcoholic individuals exhibit heightened susceptibility to acetaminophen liver injury.

    Conclusions:

    • Acetaminophen hepatotoxicity is a significant concern, even at recommended doses.
    • Alcohol consumption increases the risk of acetaminophen-induced liver damage.
    • Enhanced drug labeling is advised to inform patients and healthcare providers.